...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Traditional medicine research. >Gemcitabine and cisplatin combined with the Chinese herbal medicine compound Fuzhenggubenfang improve quality of life and progression-free survival in patients with advanced non-small cell lung cancer
【24h】

Gemcitabine and cisplatin combined with the Chinese herbal medicine compound Fuzhenggubenfang improve quality of life and progression-free survival in patients with advanced non-small cell lung cancer

机译：吉西他滨和顺铂联合中药复方骨本方改善晚期非小细胞肺癌患者的生活质量和无进展生存

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Highlights Fuzhenggubenfang could be used as promising complementary medicine in chemotherapy for advanced NSCLC to improve quality of life and progression-free survival. Editor’s Summary Fuzhenggubenfang is the Chinese herbal medicine compound created on the basis of the addition and subtraction formula from Buzhongyiqi Soup, which was first recorded in Piweilun published in 1249 A.D. (Jin Dinasty of China). Objective To assess the role of chemotherapy combined with the compound Chinese herbal medicine, Fuzhenggubenfang (FZGBF), for treating advanced non-small-cell lung cancer. Methods A total of 84 eligible patients were enrolled from October 2013 to July 2016. Patients were randomized to receive either chemotherapy alone as the control group or chemotherapy combined with FZGBF as the experimental group. The primary endpoint of the study was quality of life (QOL) and progression-free survival (PFS). Secondary endpoints were tumor response rate, toxicity, dropout rate, and univariate and multivariate analyses of clinicopathologic factors for QOL and PFS. Results There was a significant improvement in QOL, including better overall health (P P P P P 0.001), and social function (P = 0.031). Less fatigue, nausea or vomiting, insomnia, appetite loss, constipation, and alopecia were noted (All P 0.001) when FZGBF was combined with chemotherapy in comparison to chemotherapy alone. The experimental group had a better PFS compared with the control group (P = 0.032). There was no significant difference in tumor response rate. FZGBF significantly reduced chemotherapy-induced anemia (P 0.001), neutropenia (P = 0.023), nausea and vomiting (P 0.001). The use of Chinese herbal compounds had only mild side effects. In this study, factors influencing QOL were the use of the Chinese herbal compounds (P 0.001), performance status score (P = 0.027), clinical staging of cancer (P = 0.009), and sex (P = 0.044). Use of traditional Chinese medicine (P = 0.043) and the number of previous chemotherapy sessions (P = 0.003) were the factors influencing PFS in this study. Conclusion FZGBF could improve QOL, compliance to treatment, relieved chemotherapy-related toxicities of patients, and consequently improved PFS, which is a promising drug combination in complementary medicine for the treatment of advanced NSCLC.
机译：要点扶正骨本方可以作为晚期NSCLC化疗的有希望的补充药物，以改善生活质量和无进展生存期。编者的话扶正骨本方是根据补中益气汤的加减法配方制成的中草药，该药最早于公元1249年（中国金朝）出版的《皮维仑》中记载。目的探讨化学疗法联合复方骨本方（FZGBF）治疗晚期非小细胞肺癌的作用。方法从2013年10月至2016年7月，共纳入84名符合条件的患者。将患者随机分为单纯化疗组和对照组联合FZGBF组。研究的主要终点是生活质量（QOL）和无进展生存期（PFS）。次要终点是肿瘤缓解率，毒性，辍学率以及对QOL和PFS的临床病理因素的单变量和多变量分析。结果QOL显着改善，包括总体健康状况更好（P P P P P 0.001）和社会功能（P = 0.031）。与单独化疗相比，FZGBF联合化疗可减少疲劳，恶心或呕吐，失眠，食欲不振，便秘和脱发（所有P均为0.001）。与对照组相比，实验组的PFS更好（P = 0.032）。肿瘤反应率无明显差异。 FZGBF显着降低了化疗引起的贫血（P 0.001），中性粒细胞减少症（P = 0.023），恶心和呕吐（P 0.001）。使用中草药化合物只有轻微的副作用。在这项研究中，影响生活质量的因素是中草药化合物的使用（P = 0.001），性能状态评分（P = 0.027），癌症的临床分期（P = 0.009）和性别（P = 0.044）。中药的使用（P = 0.043）和既往化疗的次数（P = 0.003）是影响本研究中PFS的因素。结论FZGBF可以改善QOL，改善依从性，减轻患者的化疗相关毒性，从而改善PFS，这是治疗晚期NSCLC的有希望的补充药物组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号